Zacks Research Issues Negative Forecast for IRWD Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Zacks Research cut their Q1 2025 earnings per share estimates for Ironwood Pharmaceuticals in a research note issued to investors on Wednesday, February 12th. Zacks Research analyst R. Department now anticipates that the biotechnology company will post earnings per share of $0.01 for the quarter, down from their prior forecast of $0.03. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals' Q2 2025 earnings at $0.04 EPS, Q1 2026 earnings at $0.06 EPS, Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.11 EPS and Q4 2026 earnings at $0.10 EPS.

IRWD has been the topic of a number of other research reports. JMP Securities dropped their price objective on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a "market outperform" rating on the stock in a research report on Thursday, January 30th. StockNews.com cut Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, November 12th. Finally, Craig Hallum decreased their price target on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Wednesday, January 22nd. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $8.60.

Ironwood Pharmaceuticals Stock Performance

IRWD stock traded up $0.08 during trading on Friday, reaching $2.00. 3,581,096 shares of the company traded hands, compared to its average volume of 3,807,003. Ironwood Pharmaceuticals has a 12 month low of $1.59 and a 12 month high of $15.26. The business has a 50 day simple moving average of $3.50 and a 200 day simple moving average of $4.04. The company has a market capitalization of $320.06 million, a price-to-earnings ratio of -66.67 and a beta of 0.29.

Insider Transactions at Ironwood Pharmaceuticals

In other news, CEO Thomas A. Mccourt sold 139,064 shares of the firm's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $244,752.64. Following the completion of the transaction, the chief executive officer now directly owns 1,160,634 shares in the company, valued at $2,042,715.84. This trade represents a 10.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CMO Michael Shetzline sold 41,269 shares of the firm's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $72,633.44. Following the completion of the transaction, the chief marketing officer now owns 554,007 shares of the company's stock, valued at approximately $975,052.32. The trade was a 6.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 192,381 shares of company stock worth $338,591 over the last three months. 12.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of IRWD. Point72 Asia Singapore Pte. Ltd. purchased a new position in Ironwood Pharmaceuticals during the fourth quarter valued at approximately $36,000. KBC Group NV raised its position in Ironwood Pharmaceuticals by 59.3% during the third quarter. KBC Group NV now owns 8,593 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 3,198 shares in the last quarter. Journey Strategic Wealth LLC purchased a new position in Ironwood Pharmaceuticals during the fourth quarter valued at approximately $45,000. Catalyst Funds Management Pty Ltd purchased a new position in Ironwood Pharmaceuticals during the fourth quarter valued at approximately $47,000. Finally, Envestnet Asset Management Inc. purchased a new position in Ironwood Pharmaceuticals during the fourth quarter valued at approximately $50,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.